IMpower 133 first reported that first‐line PD‐L1 inhibitor (atezolizumab) plus chemotherapy versus chemotherapy improved the prognosis in patients with ES‐SCLC.9 This evidence concerns the gene CD274 and small cell lung carcinoma.